Objective To incorporate recent research findings, expert consensus, and patient
perspectives into updated guidance on the use of new acute and preventive treatments for …

Abstract The French Headache Society proposes updated French guidelines for the
management of migraine. This article presents the second part of the guidelines, which is …

Background: For many years triptans have been the cornerstone of acute migraine
treatment. Nevertheless, treatment with triptans may not always be initiated due to …

Background This post-hoc analysis from three phase 3 treatment trials of rimegepant 75 mg—
an oral small molecule calcitonin gene-related peptide receptor antagonist for acute and …

Background In the absence of head-to-head trials, comprehensive evidence comparing
onset of efficacy of novel agents for acute treatment of migraine is lacking. This study aimed …

Migraine is a common and disabling neurological disorder, with several manifestations, of
which pain is just one. Despite its worldwide prevalence, there remains a paucity of targeted …

After 35 years since the introduction of the International Classification of Headache
Disorders (ICHD), we are living in the era of the second great revolution in migraine …

Objective To evaluate the efficacy and safety of concurrent non‐invasive stimulation of
occipital and trigeminal nerves in acute treatment of migraine with or without aura …

Background Triptans are effective for many migraine patients, but some do not experience
adequate efficacy and tolerability. The European Headache Federation (EHF) has proposed …

Migraine constitutes the world's second-leading cause of disability. Triptans, as serotonin 5-
HT 1B/1D receptor agonists, remain the first-line treatment, despite discouraged use in …